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INTRODUCTION
Infectious diseases constitute a major public
health burden, particularly in developing
countries. Amongst the pathogens afflicting
humans, malaria, HIV, shigellosis and
tuberculosis (TB) cause a large number of
deaths. Whilst antivirals, antibiotics and anti-
parasitic drugs have all helped to reduce the
burden of disease, problems of drug resistance
are increasingly common, presenting the need
to come up with alternative approaches to
disease prevention. Ideally, effective
prophylactic vaccines would be developed
against each of these infections, but
unfortunately with the exception of TB, no
vaccine is currently available against the other
three infections. 
Baring a breakthrough, coming for example
from the application of newer more potent
adjuvants to vaccine candidates, new paradigms
are needed to help tackle these infectious
diseases. In this edition of the journal, Dr. Apte
presents his ideas for a new approach to
screening of plant extracts for anti-parasitic
drugs applying an ‘evolutionary drug design’
paradigm. Using the example of malaria, a
disease that has co-evolved with humans over
many thousands of years, he proposes that,
rather than traditional approaches based on
drugs that are parasiticidal, we should instead
try to work with the parasite, rather than against
it, developing drugs that will modify its
behavior, rather than kill it. 
In fact, revolutionary as it might sound, this
idea is not entirely new as Apte acknowledges.
For example it is the basis of all live attenuated
vaccines such as the Bacillus-Calmette-Guerin
(BCG) vaccine against TB or the live oral polio
vaccine. Live attenuated vaccines are contracts
wherein, in return for humans committing to
culture these bacteria or viruses, the pathogen
returns the favor by becoming less pathogenic
thereby helping to protect humans against more
virulent relatives. The fascinating aspect of this
relationship between humans and the
attenuated pathogens is that both benefit from
the compact. This shows the power to use
evolution to come up with mutually beneficial
arrangements. Likewise human gut commensals
have a similar compact whereby their human
host feeds and protects them while they help to
produce important nutrient compounds and
protect against colonization by pathogens. 
*Corresponding author: Flinders Medical Centre/Flinders University,
 Park, Adelaide, Australia 5042, Tel: +61-8-82044572, E-mail:
 Nikolai.petrovsky@flinders.edu.au 
This Journal is © IPEC-Americas Inc June 2013 J. Excipients and Food Chem. 4 (2) 2013 -  25 
Editorial
Can, as Dr. Apte suggests, similar concepts be
applied to the identification of plant-based
drugs whereby such drugs modulate pathogen
behavior and reduce their virulence rather than
attempt to kill the pathogen outright? In a
similar vein can the host response be
modulated with such drugs to enable infected
humans to cope with a larger parasite load? In
particular, can the burden of disease in malaria
be reduced by selective pressure directed
against only the asexual form of Plasmodium,
rather than seeking eradication of the malaria
parasite? This is an intriguing idea worthy of
further exploration. 
One problem with such an approach could be
the risk of reversion to wild-type, whereby the
attenuated pathogen reacquires its virulence.
The classic example of this is the current live
oral polio vaccine (OPV). Poliomyelitis is
caused by a polio enterovirus which has 3
serotypes, type 1, 2 & 3. Current vaccines
against poliomyelitis take two forms, i.e., the
Sabin OPV and the Salk inactivated polio
vaccine (IPV). The advantages of the OPV
includes low cost, ease of administration and
abil ity to induce robust long-term
immunization protection. The major dis-
advantage of the OPV, however, is its
propensity to revert to wild-type and thereby
cause rare cases of polio-induced paralysis. As
inactivated vaccines cannot cause disease, the
global polio eradication program will need to
switch from the OPV to IPV in order to match
the achievement of the smallpox vaccine, where
the virus was finally eradicated from nature by
an effective vaccine strategy that gave the virus
no evolutionary quarter. Hopefully the human
polio virus will similarly be driven to extinction
by similar strategies. Unlike extinctions of other
higher animals, we should not feel guilty about
such extinctions of viruses, since there is no
evidence that the world is a poorer place for
their absence.
So while strategies of evolutionary manipulation
of pathogens such as those proposed in the
associated paper in this edition of the journal
may play a valuable role in reducing the burden
of disease, they at the same time accept the
price of having to live life long with the
infecting organism, albeit with the infection
trained to be relatively asymptomatic. This will
reduce the burden of disease and save lives in
the developing world, but may lead to periodic
reversion of the parasite to wild-type and
sporadic clinical disease. Hence, it may not do
away with the need to find ways to completely
eradicate human Plasmodium strains, and this
should remain the preferred long-term solution
if it can be achieved. But innovative solutions
like those proposed by Dr. Apte may be a
beneficial interim solution and are certainly
worthy of further exploration.
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